Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Abstract Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAFV600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + MEKi caused durable melanoma regression in an immune-mediated manner. BRAFi + MEKi treatment promoted cleavage of gasdermin E (GSDME) and release of HMGB1, markers of pyroptotic cell death. GSDME-deficient melanoma showed defective HMGB1 release, reduced tumor-associated T cell and activated dendritic cell infiltrates in response to BRAFi + MEKi, and more frequent tumor regrowth after drug removal. Importantly, BRAFi + MEKi–resistant disease lacked pyroptosis markers and showed decreased intratumoral T-cell infiltration but was sensitive to pyroptosis-inducing chemotherapy. These data implicate BRAFi + MEKi–induced pyroptosis in antitumor immune responses and highlight new therapeutic strategies for resistant melanoma. Significance: Targeted inhibitors and immune checkpoint agents have advanced the care of patients with melanoma; however, detailed knowledge of the intersection between these two research areas is lacking. We describe a molecular mechanism of targeted inhibitor regulation of an immune-stimulatory form of cell death and provide a proof-of-principle salvage therapy concept for inhibitor-resistant melanoma. See related commentary by Smalley, p. 176. This article is highlighted in the In This Issue feature, p. 161
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“induction of ICD (Box 1) (Erkes et al., 2020; Wang et al., 2020a)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Erkes et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedGSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 3×
“We confirmed the ability of etoposide and also tested doxorubicin, a known chemotherapeutic inducer of pyroptosis, for ability to cause GSDME cleavage in CRT cell lines (31,32,34).”
BackgroundSelf-citationToll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundRelease of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundClassification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Self-citationInflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202 · cited 1×
“It has recently been shown that the intrinsic apoptotic pathway intersects with a distinct form of cell death termed pyroptosis that is gasderminmediated and involves pore-based release of immune stimulatory factors (28-31).”
BackgroundChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 1×
“This pore formation causes the release of immune stimulants, including HMGB1, which are able to induce dendritic cell (DC) activation and, in turn, propagate antitumor T-cell activity (32, 33, 35).”
Background
Cited by
Pyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Hou, J., Zhao, R., Xia, W., Chang, C.-W., You, Y., Hsu, J.-M., Nie, L., Chen, Y., Wang, Y.-C., Liu, C., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0575-z · Cited by 962
Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
“For instance, combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) modulate the TME by triggering pyroptosis [182].”
BackgroundRegulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
“A study in BRAFi+MEKi-resistant melanoma by using etoposide to reinduce pyroptosis, inhibition of the ERK1/2 pathway, and cleavage of GSDME-induced pyroptosis produced a more potent antitumor immune response, overcoming treatment resistance.(470) It is suggested that targeting this regulated cell death pathway represe…”
BackgroundChannelling inflammation: gasdermins in physiology and disease
Liu, X., Xia, S., Zhang, Z., Wu, H., & Lieberman, J. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00154-z · Cited by 751
The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer
Jiang, M., Qi, L., Li, L., & Li, Y. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00349-0 · Cited by 686
Hsu, S.-K., Li, C.-Y., Lin, I.-L., Syue, W.-J., Chen, Y.-F., Cheng, K.-C., Teng, Y.-N., Lin, Y.-H., Yen, C.-H., & Chiu, C.-C. (2021) · Theranostics · doi:10.7150/thno.62521 · Cited by 484
“Erikes and colleagues revealed decreased infiltration of activated DCs and T cells in GSDME-deficient melanoma [114].”
BackgroundPyroptosis: a new paradigm of cell death for fighting against cancer
Tan, Y., Chen, Q., Li, X., Zeng, Z., Xiong, W., Li, G., Li, X., Yang, J., Xiang, B., & Yi, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01959-x · Cited by 467
“Recent studies have shown that conventional treatments, including chemotherapy and targeted therapy, reverse immunosuppressive microenvironments surrounding tumor cells and re-establish local or systemic anti-tumor immunity by inducing pyroptotic cell death of tumor cells [116].”
BackgroundThe metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8
Zhang, J.-Y., Zhou, B., Sun, R.-Y., Ai, Y.-L., Cheng, K., Li, F.-N., Wang, B.-R., Liu, F.-J., Jiang, Z.-H., Wang, W.-J., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00506-9 · Cited by 392
Pyroptosis, metabolism, and tumor immune microenvironment
Du, T., Gao, J., Li, P., Wang, Y., Qi, Q., Liu, X., Li, J., Wang, C., & Du, L. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.492 · Cited by 324
Pyroptosis at the forefront of anticancer immunity
Loveless, R., Bloomquist, R., & Teng, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02065-8 · Cited by 316
Persistent Cancer Cells: The Deadly Survivors
Shen, S., Vagner, S., & Robert, C. (2020) · Cell · doi:10.1016/j.cell.2020.10.027 · Cited by 304
Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity
Hou, J., Hsu, J.-M., & Hung, M.-C. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.003 · Cited by 301
Li, J., & Kataoka, K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09029 · Cited by 281
Which cell death modality wins the contest for photodynamic therapy of cancer?
Mishchenko, T., Balalaeva, I., Gorokhova, A., Vedunova, M., & Krysko, D. V. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04851-4 · Cited by 276
“Recently, it was shown that early, but not late, ferroptotic cancer cells release classical DAMPs (e.g., ATP, HMGB1) with subsequent phenotypic maturation of BMDCs [32].”
InfluentialSwitching from Apoptosis to Pyroptosis: Gasdermin-Elicited Inflammation and Antitumor Immunity
Tsuchiya, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010426 · Cited by 255
Cell death, therapeutics, and the immune response in cancer
Hänggi, K., & Ruffell, B. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.02.001 · Cited by 237
Caspase 3/GSDME-dependent pyroptosis contributes to chemotherapy drug-induced nephrotoxicity
Shen, X., Wang, H., Weng, C., Jiang, H., & Chen, J. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03458-5 · Cited by 235
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01995-7 · Cited by 215
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Lin, W., Chen, Y., Wu, B., chen, Y., & Li, Z. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00557-2 · Cited by 209
“BRAF mutations could regulate the tumour immune microenvironment by regulating the pyroptosis-related signalling pathway [27].”
BackgroundPyroptosis, a new bridge to tumor immunity
Li, L., Jiang, M., Qi, L., Wu, Y., Song, D., Gan, J., Li, Y., & Bai, Y. (2021) · Cancer Science · doi:10.1111/cas.15059 · Cited by 201
Malireddi, R. K. S., Karki, R., Sundaram, B., Kancharana, B., Lee, S., Samir, P., & Kanneganti, T.-D. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100059 · Cited by 194
Mechanisms and Therapeutic Regulation of Pyroptosis in Inflammatory Diseases and Cancer
Zheng, Z., & Li, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041456 · Cited by 192
BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., Maddalena, P., et al. (2020) · Cancers · doi:10.3390/cancers12071823 · Cited by 186
“Combination BRAF inhibitor plus MEK inhibitor treatment has also been shown to promote the cleavage of gasdermin E and release of HMGB1, suggesting that it may in part regulate the tumour immune microenvironment through pyroptosis (an inflammatory type of programmed cell death) [47].”
BackgroundMEK inhibitor resistance mechanisms and recent developments in combination trials
Kun, E., Tsang, Y. T. M., Ng, C. W., Gershenson, D. M., & Wong, K. K. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102137 · Cited by 184
Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy
Rosenbaum, S. R., Wilski, N. A., & Aplin, A. E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0805 · Cited by 171
Self-citationJin, J., Yuan, P., Yu, W., Lin, J., Xu, A., Xu, X., Lou, J., Yu, T., Qian, C., Liu, B., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c00192 · Cited by 167
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Li, J., Chen, Y., Li, Y., Liu, N., & Ma, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01317-7 · Cited by 159
“These dual inhibitions significantly increased the intra-tumoral abundance of DCs, as well as CTLs, contributing to durable tumor regression [65].”
BackgroundSong, W., Ren, J., Xiang, R., Kong, C., & Fu, T. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1987636 · Cited by 159
“Emerging evidence also indicates crosstalk between pyroptosis and the tumor immune microenvironment.(8,9) The tumor microenvironment (TME) has been widely implicated tumor development and progression.”
BackgroundLi, J., Anraku, Y., & Kataoka, K. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004180 · Cited by 144
Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer
Lu, L., Zhang, Y., Tan, X., Merkher, Y., Leonov, S. V., Zhu, L., Deng, Y., zhang, H., Zhu, D., Tan, Y., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01101-6 · Cited by 144
“Notably, the efficacy of a BRAF-MEK inhibitor in eliminating melanoma is completely blocked in immunodeficient GSDME-positive mice, implying that the potential molecular mechanism of BRAF-MEK inhibitor treatment of melanoma is a GSDEM-dependent antitumour immune response [131].”
BackgroundGong, W. J., Xu, J., Wang, Y., Min, Q., Chen, X., Zhang, W., Chen, J., & Zhan, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00865-0 · Cited by 136
“Pyroptosis is a newly discovered programmed cell death which is closely related to inflammation and tumorigenesis.(43,44) Previous reports suggest that the decrease of mitochondrial membrane potential could lead to the augment of mitochondrial ROS.”
BackgroundWang, H., Wang, T., Yan, S., Tang, J., Zhang, Y., Wang, L., Xu, H., & Tu, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02183-9 · Cited by 133
“These may further attract and activate immune cells, particularly dendritic cells, which can then prime T cells to attack cancer cells, activating adaptive immunity [148, 149].”
Lighting a Fire: Can We Harness Pyroptosis to Ignite Antitumor Immunity?
Zhang, Z., Zhang, Y., & Lieberman, J. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0525 · Cited by 126
“Another study showed that combination treatment with a BRAF inhibitor and a MEK inhibitor induces GSDME-mediated pyroptosis to activate antitumor immunity in GSDME-expressing melanoma (39).”
BackgroundTargeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
Huang, C. L., Li, J., Wu, R., Li, Y., & Zhang, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02344-4 · Cited by 127
“Tumor cell pyroptosis can not only activate CTLs [266, 267], but also increase the number of CD4 + T and CD8 + T cells [130].”
GSDME and its role in cancer: From behind the scenes to the front of the stage
Schutter, E. D., Croes, L., Ibrahim, J., Pauwels, P., de Beeck, K. O., Vandenabeele, P., & Camp, G. V. (2020) · International Journal of Cancer · doi:10.1002/ijc.33390 · Cited by 120
“associated T cell and activated dendritic cell infiltrates in response to BRAFi + MEKi treatment compared to the control counterparts.(68) As GSDME KO tumors also showed more frequent tumor regrowth after”
BackgroundResultGuo, Z., Liu, Y., Chen, D., Sun, Y., Li, D., Meng, Y., Zhou, Q., Zeng, F., Deng, G., & Chen, X. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0004 · Cited by 124
“…drug GSDMD Pyroptosis induction [278] Enhanced antitumor immunity [292] BRAF and MEK Inhibitor Anticancer drug GSDMD Pyroptosis induction [173] Enhanced antitumor immunity [173] Cisplatin Anticancer drug GSH/GSDME Pyroptosis induction [293] Enhanced antitumor immunity [294] Doxorubicin…”
InfluentialMEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
de Blank, P. M. K., Gross, A. M., Akshintala, S., Blakeley, J. O., Bollag, G. E., Cannon, A. D., Dombi, E., Fangusaro, J., Gelb, B. D., Hargrave, D. R., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac165 · Cited by 121
Emerging role of immunogenic cell death in cancer immunotherapy
Arimoto, K., Miyauchi, S., Liu, M., & Zhang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1390263 · Cited by 116
Induction of Pyroptosis: A Promising Strategy for Cancer Treatment
Wang, L., Qin, X., Liang, J., & Ge, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635774 · Cited by 113
“For BRAFi + MEKi-resistant melanoma, switching to other chemotherapeutic drugs such as etoposide that induces pyroptosis may be an effective strategy (94).”
BackgroundInfluentialJu, A., Tang, J., Chen, S., Fu, Y., & Luo, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.709077 · Cited by 111
“In addition to immune checkpoint therapy, 318 some commonly used melanoma-targeting drugs, including BRAF and MEK inhibitors, also affect the 319 immune microenvironment through pyroptosis (49).”
BackgroundTargeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis
Zhou, W., Liu, H., Yuan, Z., Zundell, J. A., Towers, M., Lin, J., Lombardi, S., Nie, H., Murphy, B., Yang, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.002 · Cited by 109
Unveiling the role of KRAS in tumor immune microenvironment
Xu, M., Zhao, X., Wen, T., & Qu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116058 · Cited by 102
Deng, M., Sun, S., Zhao, R., Guan, R., Zhang, Z., Li, S., Wei, W., & Guo, R. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00445-0 · Cited by 99
Wan, S., Zhang, G., Liu, R., Abbas, M. N., & Cui, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01108-1 · Cited by 99
Pyroptosis in Cancer: Friend or Foe?
Lu, X., Guo, T., & Zhang, X. (2021) · Cancers · doi:10.3390/cancers13143620 · Cited by 92
“BRAF inhibitors together with MEK inhibitors could induce pyroptosis in melanoma with a higher HMGB1, more tumor-associated T cells, and less dendritic cell infiltration, while GSDME deficiency would reverse the anti-tumor immunity [91] (Tables 2 and 3).”
BackgroundNanomedicine‐Enabled/Augmented Cell Pyroptosis for Efficient Tumor Nanotherapy
Zhang, Z., Zhou, Y., Zhao, S., Ding, L., Chen, B., & Chen, Y. (2022) · Advanced Science · doi:10.1002/advs.202203583 · Cited by 89
Li, Q., Yu, L., Gao, A., Ren, R., Zhang, J., Cao, L., Wang, X., Liu, Y., Qi, W., Cai, L., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318451 · Cited by 88
HMGB1 in the interplay between autophagy and apoptosis in cancer
Chen, R., Zou, J., Zhong, X. Y., Li, J., Kang, R., & Tang, D. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216494 · Cited by 87
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02100-8 · Cited by 87
Novel necroptosis-related gene signature for predicting the prognosis of pancreatic adenocarcinoma
Wu, Z., Huang, X., Cai, M., Huang, P., & Guan, Z. (2022) · Aging · doi:10.18632/aging.203846 · Cited by 86
“Necroptotic programmed cell death is an alternate method of programmed cell death, which can address apoptosis resistance and activate and enhance antitumor immunity in cancer treatment [22].”
MethodUSP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Ren, Y., Feng, M., Hao, X., Liu, X., Li, J., Li, P., Gao, J., Qi, Q., Du, L., Wang, C., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1812 · Cited by 85
Immunogenic cell death in cancer immunotherapy
Choi, M., Shin, J., Lee, C.-E., Chung, J.-Y., Kim, M., Yan, X., Yang, W., & Cha, J. (2023) · BMB Reports · doi:10.5483/bmbrep.2023-0024 · Cited by 85
“A recent clinical trial (NCT029 21854) is investigating whether ICD markers such as HMGB1, HSP70, HSP90, and CRT can be detected in serum after non-small cell lung cancer (NSCLC) patients are treated with radiation therapy and cisplatin, a chemotherapeutic agent (122).”
BackgroundInfluentialCao, W., Chen, G., Wu, L., Yu, K. N., Sun, M., Yang, M., Jiang, Y., Jiang, Y., Yuan, X., Peng, S., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.1841 · Cited by 83
The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy
Deng, W., Shang, H., Tong, Y., Liu, X., Huang, Q., He, Y. T., Wu, J., Ba, X., Chen, Z., Chen, Y., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02297-8 · Cited by 83
“Previous studies have suggested that molecular inhibitors targeting oncogenic signaling pathways can also induce GSDME-mediated pyrop-totic death in tumor cells [256, 257].”
BackgroundLu, H., Wu, J., Liang, L., Wang, X., & Cai, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.803355 · Cited by 79
“Recently, a study showed that pyroptotic cancer death could activate tumor-associated T-cell and dendritic cell (DC) infiltrations (12).”
BackgroundNon-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis
Liu, Y., Chen, Q., Zhu, Y., Wang, T., Ye, L., Han, L., Yao, Z., & Yang, Z. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00596-9 · Cited by 78
“In recent years, researchers have discovered that pyrolysis is closely related to a variety of human diseases, such as infectious diseases, cardiovascular and cerebrovascular diseases, immune system defects, and tumors [57, 58].”
BackgroundCrosstalk between metabolism and cell death in tumorigenesis
Yang, S., Hu, C., Chen, X., Tang, Y., Li, J., Yang, H., Yang, Y., Ying, B., Xiao, X., Li, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01977-1 · Cited by 77
“NLRP3 inflammasome activation, such as IL-1β and IL-18 production, promotes immune cell infiltration in the tumor microenvironment and enhances chemotherapy-induced anti-tumor immunity [218, 219].”
BackgroundXu, D., Ji, Z., & Qiang, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.702638 · Cited by 75
“Inducing apoptosis of cancer cells has been applied for eliminating malignant cells (28).”
BackgroundIntestinal Candida albicans Promotes Hepatocarcinogenesis by Up-Regulating NLRP6
Liu, Z., Li, Y., Li, C., Lei, G., Zhou, L., Chen, X., Jia, X., & Lu, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.812771 · Cited by 75
PANoptosis in cancer: bridging molecular mechanisms to therapeutic innovations
Lin, J., Wang, T., Huang, R., Tan, Y., Chen, D., & Ju, H. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01329-z · Cited by 76
Regulation of Lytic and Non-Lytic Functions of Gasdermin Pores
Rühl, S., & Broz, P. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167246 · Cited by 74
Non-Apoptotic Cell Death Signaling Pathways in Melanoma
Hartman, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082980 · Cited by 74
“Notably, BRAFi- and MEKi-resistant cells were still sensitive to pyroptosis-inducing compounds [222].”
BackgroundPyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective
Khan, M. B., Ai, M.-L., Du, K., Song, J., Wang, B., Lin, J., Ren, A., Chen, C., Huang, Z., Qiu, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1062225 · Cited by 73
“The combination of BRAF and MEK inhibitors was shown to induce pyroptosis in melanoma cells via GSDME which resulted in an increase in CD4+ T cell and CD8+ T cell infiltration and a decrease in myeloid-derived suppressor cells (MDSCs) and tumorassociated macrophages (TAMs) (67, 68).”
BackgroundPyroptosis Provides New Strategies for the Treatment of Cancer
Jia, Y., Wang, X., Deng, Y., Li, S., Xu, X., Qin, Y., & Peng, L. J. (2023) · Journal of Cancer · doi:10.7150/jca.77965 · Cited by 73
“A study in melanoma confirmed that the combination of BRAFi and MEKi could have an antitumor effect through GSDME induced pyroptosis [77], DDP combined with BI2536 (PLK1 kinase inhibitor) can cause esophageal cancer cell pyroptosis[110].”
BackgroundThe role of pyroptosis and gasdermin family in tumor progression and immune microenvironment
Li, M., Jiang, P., Yang, Y., Xiong, L., Wei, S., Wang, J., & Li, C. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00464-5 · Cited by 71
“In melanoma, a combination of a BRAF inhibitor and a MEK inhibitor-induced GSDME-mediated pyroptosis, contributes to increased antitumor immunity [184].”
BackgroundMelanoma biology and treatment: a review of novel regulated cell death-based approaches
Hsieh, M.-Y., Hsu, S., Liu, T., Wu, C., & Chiu, C. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03220-9 · Cited by 71
“After treatment with BRAF/MEK inhibitors, melanoma cells lacking GSDME exhibited impaired infiltration of tumor-associated T cells, the number of activated dendritic cells was diminished, and a higher incidence of tumor regrowth after cessation of drug treatment was recorded [74].”
BackgroundMethodInfluentialAraujo, H. A., Pechuan-Jorge, X., Zhou, T., Do, M. T., Hu, X., Rojas Alvarez, F. R., Salvatierra, M. E., Ibarguen, H. P., Lee, R., Raghulan, R., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0421 · Cited by 70
The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy
Wang, H., Zhou, X., Li, C., Yan, S., Feng, C., He, J., Li, Z., & Tu, C. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01365-6 · Cited by 69
“Further studies found that BRAFi/MEKi can induce pyroptosis with cleavage of GSDME and release of proinflammation factors like high mobility group protein B1 (HMGB1, an inflammatory marker of pyroptosis) [73].”
BackgroundLysosomal lipid peroxidation regulates tumor immunity
Bhardwaj, M., Lee, J. J., Versace, A. M., Harper, S. L., Goldman, A. R., Crissey, M. A. S., Jain, V., Singh, M. P., Vernon, M., Aplin, A. E., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164596 · Cited by 69
Self-citationXiong, H., Ma, X., Wang, X., Su, W., Wu, L., Zhang, T., Xu, Z., & Sun, Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100007 · Cited by 68
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
“Recently, dual BRAF and MEK inhibition was also shown to induce anti-tumor immunity via the induction of pyroptosis; a type of in fl ammatory cell death that promotes DC activation and subsequent T cell immunity (107).”
BackgroundThe multifaceted roles of gasdermins in cancer biology and oncologic therapies
Sarrió, D., Martínez-Val, J., Molina-Crespo, Á., Sanchez, L. E., & Moreno‐Bueno, G. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188635 · Cited by 65
Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03940-y · Cited by 63
Jin, X., Jin, W., Tong, L., Zhao, J., Zhang, L., & Lin, N. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.020 · Cited by 64
“BRAF ,inducingpyroptosistoreducethe viability of BRAF mutant melanoma cells 347 .”
Pyroptosis: A promising therapeutic target for noninfectious diseases
Li, T., Zheng, G., Li, B., & Tang, L. (2021) · Cell Proliferation · doi:10.1111/cpr.13137 · Cited by 63
A Novel Pyroptosis-Related lncRNA Signature for Predicting the Prognosis of Skin Cutaneous Melanoma
Xie, J., Li, H., Liang, C., Cao, Y., Hu, Y., Zhu, Z., Wang, M., & Shi, J. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s335396 · Cited by 62
Sang, R., Fan, R., Deng, A., Gou, J., Lin, R., Zhao, T., Hai, Y., Song, J., Liu, Y., Qi, B., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00118 · Cited by 62
Gasdermin E: A Prospective Target for Therapy of Diseases
Liao, X.-X., Dai, Y., Zhao, Y., & Nie, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.855828 · Cited by 61
Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies
Wang, W., Zhang, L., & Sun, Z. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0049 · Cited by 60
Liu, Z., Wang, C., & Lin, C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121498 · Cited by 60
Pyroptosis in cancer therapy: a double-edged sword for immune activation and tumor progression
Alishvandi, A., Aram, C., Shahrivar, F. F., Kesharwani, P., & Sahebkar, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02506-4 · Cited by 62
“This underscores that immune system reactions are required for inducing pyroptosis via the GSDME-dependent pathway [387].”
Wu, L., Zhang, Y., Yang, Y., Lin, B., Zhu, M., Xu, J., Chen, Y., Wu, W., Chen, B., Chen, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202303908 · Cited by 59
CTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma
Wang, S., Wu, Z., Zhu, S., Wan, S., Zhang, M.-J., Zhang, B., Yang, Q., Xiao, Y., Li, H., Mao, L., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.023 · Cited by 58
Role of pyroptosis in cancer cells and clinical applications
Ju, X., Yang, Z., Zhang, H., & Wang, Q. (2021) · Biochimie · doi:10.1016/j.biochi.2021.03.007 · Cited by 58
Pyroptosis, a New Breakthrough in Cancer Treatment
Wu, D., Wei, C., Li, Y., Yang, X., & Zhou, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698811 · Cited by 57
Zhang, Y.-F., Zhou, L., Mao, H., Yang, F.-H., Chen, Z., & Zhang, L. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00770-z · Cited by 57
Liu, X., Baer, J. M., Stone, M. L., Knolhoff, B. L., Hogg, G. D., Turner, M. C., Kao, Y., Weinstein, A. G., Ahmad, F. F., Chen, J., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado2402 · Cited by 57
“Previous studies have implicated the immune-modulating activity of FAKi and RAF-MEKi as single agents ( 22 , 23 , 35 , 36 ).”
BackgroundZhao, Q., Feng, H., Yang, Z., Liang, J., Jin, Z., Chen, L., Zhan, L., Xuan, M., Yan, J., Kuang, J., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.727 · Cited by 55
The role of pyroptosis in modulating the tumor immune microenvironment
Wu, J., Wang, L., & Xu, J. (2022) · Biomarker Research · doi:10.1186/s40364-022-00391-3 · Cited by 55
“GSDME-deficient melanoma showed defective HMGB1 release, decreased tumor-associated T cells, and activated DC infiltrates in response to BRAFi + MEKi, and more frequent tumor regrowth was observed after drug removal [82].”
BackgroundWang, Y., Wang, Y., Pan, J., Gan, L., & Xue, J. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109689 · Cited by 55
Phadke, M. S., Chen, Z., Li, J., Mohamed, E. T., Davies, M. A., Smalley, I., Duckett, D. R., Palve, V. C., Czerniecki, B. J., Forsyth, P. A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0905 · Cited by 54
“In the immunecompetent mice, BRAF–MEK inhibition is associated with vigorous infiltration of CD4þ and CD8þ T cells, and reduced levels of protumorigenic macrophages (32).”
BackgroundFattore, L., Cafaro, G., Martile, M. D., Campani, V., Sacconi, A., Liguoro, D., Marra, E., Bruschini, S., Stoppoloni, D., Cirombella, R., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02547-9 · Cited by 54
“We are also aware that a limitation is the use of partially immunodeficient mouse models that still have macrophages but lack of other immune cells, like all the classes of lymphocytes [41].”
BackgroundCholesterol Metabolism in Cancer and Cell Death
Chen, F., Lu, Y., Lin, J., Kang, R., & Liu, J. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0340 · Cited by 53
“Moreover, membrane cholesterol efflux increases interleukin (IL)-4 signaling and inhibits interferon gamma (IFN c )-induced gene expression in a metastatic ovarian cancer mouse model, promoting the tumor-promoting function of TAMs, whereas the inhibition of ABC transporters reverts the tumor-promoting function of TAMs…”
InfluentialPyroptosis, a target for cancer treatment?
Huang, Y., Wang, J., Huang, J., Tang, L., Xu, Y., Sun, H., Tang, J., & Wang, G. (2022) · APOPTOSIS · doi:10.1007/s10495-021-01703-y · Cited by 53
Molecular mechanisms of pyroptosis and its role in anti-tumor immunity
Huang, H., Weng, Y., Tian, W., Lin, X., Chen, J., & Luo, L. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.86855 · Cited by 52
“Pyroptosis induced by this pathway enhances the maturation of DCs, the frequency of effector memory T cells, and the inhibition of tumor growth, demonstrating superior antitumor immunity[120].”
MethodInfluentialGasdermin C sensitizes tumor cells to PARP inhibitor therapy in cancer models
Wang, S., Chang, C.-W. M., Huang, J., Zeng, S., Zhang, X., Hung, M., & Hou, J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166841 · Cited by 52
“It has been reported that high mobility group box 1 (HMGB1) could both promote tumor cell proliferation (25) and enhance T cell–dependent antitumor immunity (26).”
Background
Metadata
- Authors
- Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., & Aplin, A. E.
- Affiliations
- Thomas Jefferson University (US)
- Corresponding author
- Alnemri, Emad S.
- Aplin, Andrew E.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-02-01
- Volume
- 10
- Issue
- 2
- Pages
- 254-269
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7007378
- OpenAlex
- W2993434511
- Cited by
- 459
- References
- 67
- Citations by year
- 2026: 38 · 2025: 52 · 2024: 78 · 2023: 84 · 2022: 114 · 2021: 72 · 2020: 21
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (CA196278, CA160495, CA182635, CA207855)
- Dr. Ralph and Marian Falk Medical Research Trust (N/A)
- HHS | National Institutes of Health (AR055398, AR074564)
- U.S. Department of Defense (PC150650)
- American Cancer Society (PF-18-096-01-LIB)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- BRAF inhibitors, MEK inhibitors, pyroptosis, gasdermin E, HMGB1, tumor immune microenvironment, antitumor immunity, T cell infiltration, dendritic cells, drug resistance, salvage therapy, targeted therapy
- MeSH terms
- Pyroptosis, Proof of Concept Study, Immune Checkpoint Inhibitors, Animals, Antineoplastic Combined Chemotherapy Protocols, Dendritic Cells, Disease Models, Animal, Female, Humans, Male, Melanoma, Mutation, Skin Neoplasms, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.